Volume : 12, Issue : 03, March – 2025
Title:
A REVIEW ON DAPAGLIFLOZIN: A SODIUM-GLUCOSE CO TRANSPORTER 2(SGLT2) INHIBITOR FOR THE TREATMENT OF TYPE2 DIABETES MELLITUS
Authors :
Dr. S. Kusuma Kumari*, V. Venkateshwari
Abstract :
Diabetes mellitus (Type 2) is a major world health problem spreading speedily throughout the world. It is a chronic illness that necessitates long-term therapy and care. Therefore, the therapy to treat and manage the disease should not only be safe and effective but should also be affordable. Despite the availability of multiple antidiabetic medications, T2DM is still associated with significant morbidity and mortality. Chronic hyperglycaemia can lead to renal failure, cardiovascular complications including stroke and heart disease, sight loss associated with diabetic retinopathy and maculopathy, and limb amputations due to diabetic neuropathy. This review article mainly focuses on the novel drug dapagliflozin, a SGLT-2 inhibitor, and discusses its various aspects. Dapagliflozin received FDA approval in January 2014. The drug is indicated in adult patients with type 2 DM to improve blood glucose control in addition to diet and exercise. Other indications include for patients with heart failure, it can be helpful at reducing the worsening of heart failure symptoms and lower hospital admissions caused by these. It can also be effective in people with heart failure who do not have type 2 diabetes. Dapagliflozin is not for weight loss or blood pressure management, but it can help with both. Dapagliflozin is effective as both, monotherapy and combination therapy depending on the severity of the case as indicated by multiple studies. Since, only one daily dose is sufficient, this may be a more reasonable option for many low-income group patients. The contraindications include Serious hypersensitivity to dapagliflozin (e.g., anaphylaxis, angioedema), Patients on dialysis. Finally, Dapagliflozin is a favourable drug that is not only safe and effective but is well tolerated in patients with T2DM. With its high efficiency, the ability to control glucose levels in the body, and mild blood pressure lowering abilities.
Keywords: TypeII Diabetes Mellitus, Dapagliflozin, Hypersensitivity Reactions, Anaphylaxis, Angioedema
Cite This Article:
Please cite this article in press S. Kusuma Kumari et al., A Review On Dapagliflozin: A Sodium-Glucose Co Transporter 2(SGLT2) Inhibitor For The Treatment Of Type2 Diabetes Mellitus.,Indo Am. J. P. Sci, 2025; 12 (03)
Number of Downloads : 10
References:
1.S. Kasichayanula, X. Liu, F. LaCreta, S.C. Griffen, D.W. Boulton Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2 Clin. Pharmacokinet., 53 (2014), pp. 17-27.
2. Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(17):2289–2312. doi: 10.2165/11209910-000000000-00000.
3. P. Saeedi, I. Petersohn, P. Salpea, B. Malanda, S. Karuranga, N. Unwin, S. Colagiuri, L. Guariguata, A.A. Motala, K. Ogurtsova, J.E. Shaw Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, diabetes res Clin. Pract. (Wash. D C), 157 (2019), Article 107843.
4. Unnikrishnan R, Anjana RM, Mohan V. Diabetes mellitus and its complications in India. Nature Reviews Endocrinology. 2016 Jun;12(6):357-70.
5. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108–2117. doi: 10.1007/s00125-018-4670-7.